BKR-017

DIETARY_SUPPLEMENT4 trials

Sponsors

Mayo Clinic, BioKier Inc.

Conditions

HypercholesterolemiaType 2 DiabetesType1diabetes

Phase 1

Butyrate Adjuvant Therapy for Type 1 Diabetes

CompletedNCT03999853

Mayo ClinicType1diabetes

Start: 2022-07-28End: 2025-12-01Updated: 2026-03-31

Unknown Phase

Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients

CompletedNCT04279444

BioKier Inc.Type 2 Diabetes

Start: 2020-06-16End: 2020-11-15Updated: 2020-12-04

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

CompletedNCT04673656

BioKier Inc.Type 2 Diabetes

Start: 2021-04-18End: 2023-02-07Updated: 2023-02-08

Pharmacokinetics of Butyrate Tablet BKR-017

CompletedNCT06556745

BioKier Inc.Hypercholesterolemia

Start: 2025-07-16End: 2026-06-04Updated: 2026-06-09